Safety and efficacy of alemtuzumab in the treatment of late acute renal allograft rejection
Article first published online: 24 NOV 2011
© 2011 John Wiley & Sons A/S
Volume 16, Issue 3, pages 286–293, May 2012
How to Cite
Upadhyay, K., Midgley, L. and Moudgil, A. (2012), Safety and efficacy of alemtuzumab in the treatment of late acute renal allograft rejection. Pediatric Transplantation, 16: 286–293. doi: 10.1111/j.1399-3046.2011.01615.x
- Issue published online: 10 APR 2012
- Article first published online: 24 NOV 2011
- Accepted for publication 27 September 2011
- acute rejection;
- renal transplantation
Upadhyay K, Midgley L, Moudgil A. Safety and efficacy of alemtuzumab in the treatment of late acute renal allograft rejection.
Abstract: Safety and efficacy of alemtuzumab in the treatment of AR in children after renal transplantation is unknown. Five episodes of refractory late AR in three children (three episodes in patient 1 and a single episode in patients 2 and 3 occurring after 7–23 months of transplantation) were treated with one dose of alemtuzumab as a rescue therapy. Four episodes (Banff IA-IB) in patients 1 and 2 reversed fully or partially with alemtuzumab, whereas patient 3 with Banff IB-IIA AR failed to respond. Patient 1 had recurrent AR 5, 13, and 15 months later; first two episodes responded to retreatment with alemtuzumab, and the last episode was not treated causing allograft failure. Patient 2 had steroid-responsive AR after two months and had a functioning allograft 25 months later. A transient reduction in all lymphocyte subsets except natural killer cells occurred in all patients. Patient 3 (treated with steroids, ThymoglobulinR, intravenous immunoglobulin, and rituximab prior to alemtuzumab) suffered many bacterial infections during one-yr period after therapy. However, symptomatic viral infections were not observed in any of the children. Treatment with alemtuzumab may prolong allograft survival in multidrug-resistant AR but may not prevent recurrent AR in non-adherent children.